Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
2008/11/23 by Gilbert Bensimon, Albert Ludolph, Yves Agid +3 · 28 citations
Medicine · Neuroscience · #Amyotrophic lateral sclerosis #Atrophy #Clinical endpoint #Disease #Internal medicine #Medicine #Neurological diseases and metabolism #Neurological disorders and treatments #Parkinson's Disease Mechanisms and Treatments #Parkinson's disease #Pathology #Placebo #Progressive supranuclear palsy #Randomized controlled trial #Riluzole
paper · pdf · doi:10.1093/brain/awn291
openalex publication_date 2008/11/23 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Abstract
Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-rigid syndrome diagnosed as having PSP or MSA according to modified consensus diagnostic criteria were considered for inclusion. The psychometric validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested prospectively by clinical and pathological assessments. The study was powered to detect a 40% decrease in relative risk of death within PSP or MSA strata. Patients were randomized to riluzole or matched placebo daily and followed up to 36 months. The primary endpoint was survival. Secondary efficacy outcomes were rates of disease progression assessed by functional measures. A total of 767 patients were randomized and 760 qualified for the Intent to Treat (ITT) analysis, stratified at entry as PSP (362 patients) or MSA (398 patients). Median follow-up was 1095 days (range 249-1095). During the study, 342 patients died and 112 brains were examined for pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent convergent validity with the investigators' assessment of diagnostic probability (point-biserial correlation: MSA r(pb) = 0.93, P < 0.0001; PSP, r(pb) = 0.95, P < 0.0001), and excellent predictive validity against histopathology [sensitivity and specificity (95% CI) for PSP 0.95 (0.88-0.98) and 0.84 (0.77-0.87); and for MSA 0.96 (0.88-0.99) and 0.91 (0.86-0.93)]. There was no evidence of a drug effect on survival in the PSP or MSA strata (3 year Kaplan-Meier estimates PSP-riluzole: 0.51, PSP-placebo: 0.50; MSA-riluzole: 0.53, MSA-placebo: 0.58; P = 0.66 and P = 0.48 by the log-rank test, respectively), or in the population as a whole (P = 0.42, by the stratified-log-rank test). Likewise, rate of progression was similar in both treatment groups. There were no unexpected adverse effects of riluzole, and no significant safety concerns. Riluzole did not have a significant effect on survival or rate of functional deterioration in PSP or MSA, although the study reached over 80% power to detect the hypothesized drug effect within strata. The NNIPPS diagnostic criteria were consistent and valid. They can be used to distinguish between PSP and MSA with high accuracy, and should facilitate research into these conditions relatively early in their evolution.
Cited by
- Multiple system atrophy: cure and care
- Managing Advanced Progressive Supranuclear Palsy and Corticobasal Degeneration in a Palliative Care Unit
- Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy
- A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? [europepmc]
- Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. [europepmc]
- Social cognitive deficits and their neural correlates in progressive supranuclear palsy. [europepmc]
- The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). [europepmc]
- Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. [europepmc]
- Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. [europepmc]
- The natural history of multiple system atrophy: a prospective European cohort study. [europepmc]
- Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. [europepmc]
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. [europepmc]
- Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. [europepmc]
- Natural history of multiple system atrophy in the USA: a prospective cohort study. [europepmc]
- Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. [europepmc]
- Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. [europepmc]
- Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. [europepmc]
- 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. [europepmc]
- Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. [europepmc]
- Symptom Clusters of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Comparative Risks of Dementia: A Cohort Study of 8530 Older Persons. [europepmc]
- Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. [europepmc]
- Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial. [europepmc]
- Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia. [europepmc]
- Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. [europepmc]
- Progressive supranuclear palsy: Advances in diagnosis and management. [europepmc]
- Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. [europepmc]
- Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. [europepmc]
- Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. [europepmc]
Related